HRP20100115T1 - Protutijela protiv peptida amiloid-beta - Google Patents
Protutijela protiv peptida amiloid-beta Download PDFInfo
- Publication number
- HRP20100115T1 HRP20100115T1 HR20100115T HRP20100115T HRP20100115T1 HR P20100115 T1 HRP20100115 T1 HR P20100115T1 HR 20100115 T HR20100115 T HR 20100115T HR P20100115 T HRP20100115 T HR P20100115T HR P20100115 T1 HRP20100115 T1 HR P20100115T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- dna
- heavy chain
- set forth
- amino acid
- Prior art date
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 claims abstract 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 108020004414 DNA Proteins 0.000 claims 11
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 230000035772 mutation Effects 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 230000024203 complement activation Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Terapijsko protutijelo, naznačeno time što sadrži VH lanac sa slijedom iznijetim u SEQ ID No:26 i VL domenu sa slijedom iznijetim u SEQ ID No:32. Patent sadrži još 13 patentnih zahtjeva.
Claims (14)
1. Terapijsko protutijelo, naznačeno time što sadrži VH lanac sa slijedom iznijetim u SEQ ID No:26 i VL domenu sa slijedom iznijetim u SEQ ID No:32.
2. Terapijsko protutijelo, naznačeno time što sadrži VH lanac sa slijedom iznijetim u SEQ ID No:28 i VL domenu sa slijedom iznijetim u SEQ ID No:32.
3. Terapijsko protutijelo, naznačeno time što sadrži VH lanac sa slijedom iznijetim u SEQ ID No:30 i VL domenu sa slijedom iznijetim u SEQ ID No:32.
4. Terapijsko protutijelo u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time što je IgG1 izo tipa.
5. Terapijsko protutijelo u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time što mu nedostaju funkcije a) aktivacije komplementa klasičnim putem; i b) posredovanja kod o protutijelu ovisne stanične citotoksičnosti.
6. Terapijsko protutijelo u skladu s patentnim zahtjevom 4, naznačeno time što su mu ostaci 235 i 237 mutirani u alanin.
7. Terapijsko protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što sadrži teški lanac sa slijedom iznijetim u SEQ ID No:34, 36 ili 38 i laki lanac sa slijedom iznijetim u SEQ ID No:40.
8. Farmaceutski pripravak, naznačen time što sadrži terapijsko protutijelo u skladu s bilo kojim od prethodnih patentnih zahtjeva.
9. Terapijsko protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačeno time što je namijenjeno upotrebi u liječenju bolesti povezane s β-amiloidnim peptidom.
10. Terapijsko protutijelo u skladu s patentnim zahtjevom 9, naznačeno time što bolest povezana s β-amiloidnim peptidom je Alzheimerova bolest.
11. Protutijelo, ili njegov fragment, naznačeno time što sadrži VH domenu sa slijedom iznijetim u SEQ ID No:17 i VL domenu sa slijedom iznijetim u SEQ ID No:19.
12. Polinukleotid koji kodira teški lanac terapijskog protutijela, naznačen time što navedeni polinukleotid ima slijed iznijet u SEQ ID No:35, 37, 39 ili 42.
13. Polinukleotid koji kodira laki lanac terapijskog protutijela, naznačen time što navedeni polinukleotid ima slijed iznijet u SEQ ID No:41 ili 43.
14. Postupak proizvodnje terapijskog protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što navedeni postupak se sastoji u ekspresiji polinukleotida koji kodira navedeno protutijelo u stanici domaćinu.
SEKVENCE
2E7 VH aminokiselinski slijed (SEQ ID No:17)
EVKLVESGGGLVQPGGSLKLSCAVSGFTFSDNGMAWVRQAPRKGPEWIAFISNLAYSIDYADTVTGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCVSGTWFAYWGQGTLVTVSA
2E7 VH DNA slijed (SEQ ID No:18)
GAGGTGAAGCTGGTGGAGTCTGGGGGAGGCTTAGTGCAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAGTCTCTGGATTCACTTTCAGTGACAACGGAATGGCGTGGGTTCGACAGGCTCCAAGGAAGGGGCCTGAGTGGATAGCGTTCATTAGTAATTTGGCATATAGTATCGACTACGCAGACACTGTGACGGGCCGATTCACCATCTCTAGAGATAATGCCAAGAATACCCTGTACCTGGAAATGAGCAGTCTGAGGTCTGAGGACACGGCCATGTACTATTGTGTAAGCGGGACCTGGTTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA
2E7 VL aminokiselinski slijed (SEQ ID No:19)
DVVLTQTPLSLPVSLGDQASISCRVSQSLLHSNGYTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQTRHVPYTFGGGTKLEIK
2E7 VL DNA slijed ((SEQ ID No:20)
GATGTTGTGCTGACCCAAACTCCACTCTCCCTGCCTGTCAGTCTTGGAGATCAAGCCTCCATCTCTTGCAGAGTTAGTCAGAGCCTTTTACACAGTAATGGATACACCTATTTACATTGGTACCTGCAGAAGCCAGGCCAGTCTCCAAAGCTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAGCAGAGTGGAGGCTGAGGATCTGGGAGTTTATTTCTGCTCTCAAACTAGACATGTTCCGTACACGTTCGGAGGGGGGACCAAGCTGGAAATAAAA
M99675 akceptor teškog lanca okvir čitanja V regije, aminokiselinski slijed (SEQ ID No:21)
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR
M99675 akceptor teškog lanca okvir čitanja V regije, DNA
(SEQ ID No:22)
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAGCATGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTAGTAGTACCATATACTACGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGA
CAA51135 akceptor lakog lanca okvir čitanja V regije, aminokiselinski slijed (SEQ ID No:24)
DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPWTFGQGTKVEIK
CAA51135 akceptor lakog lanca okvir čitanja V regije, DNA
(SEQ ID No:25)
GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAAACTCCGTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA
Humanizirani teški lanac V regije varijanta H1, aminokiselinski slijed (SEQ ID No:26)
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDNGMAWVRQAPGKGLEWVSFISNLAYSIDYADTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCVSGTWFAYWGQGTLVTVSS
Humanizirani teški lanac V regije varijanta H1,
DNA kodirajući slijed (SEQ ID No:27)
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTGACAACGGAATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTTCATTCATTAGTAATTTGGCATATAGTATCGACTACGCAGACACTGTGACGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGTCAGCGGGACCTGGTTTGCTTACTGGGGCCAGGGCACACTAGTCACAGTCTCCTCA
Humanizirani teški lanac V regije varijanta H2, aminokiselinski slijed (SEQ ID No:28)
EVQLVESGGGLVQPGGSLRLSCAVSGFTFSDNGMAWVRQAPGKGLEWVSFISNLAYSIDYADTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCVSGTWFAYWGQGTLVTVSS
Humanizirani teški lanac V regije varijanta H2, DNA
(SEQ ID No:29)
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGTCTCTGGATTCACCTTCAGTGACAACGGAATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTTCATTCATTAGTAATTTGGCATATAGTATCGACTACGCAGACACTGTGACGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGTCAGCGGGACCTGGTTTGCTTACTGGGGCCAGGGCACACTAGTCACAGTCTCCTCA
Humanizirani teški lanac V regije varijanta H3, aminokiselinski slijed (SEQ ID No:30)
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDNGMAWVRQAPGKGLEWISFISNLAYSIDYADTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCVSGTWFAYWGQGTLVTVSS
Humanizirani teški lanac V regije varijanta H3, DNA
(SEQ ID No:31)
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTGACAACGGAATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCTCATTCATTAGTAATTTGGCATATAGTATCGACTACGCAGACACTGTGACGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGTCAGCGGGACCTGGTTTGCTTACTGGGGCCAGGGCACACTAGTCACAGTCTCCTCA
Humanizirani laki lanac V regije varijanta L1, aminokiselinski slijed (SEQ ID No:32)
DIVMTQSPLSLPVTPGEPASISCRVSQSLLHSNGYTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQTRHVPYTFGGGTKVEIK
Humanizirani laki lanac V regije varijanta L1, DNA
(SEQ ID No:33)
GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGAGTTAGTCAGAGCCTTTTACACAGTAATGGATACACCTATTTACATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATAAAGTTTCCAACCGATTTTCTGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCTCTCAAACTAGACATGTTCCGTACACGTTCGGCGGAGGGACCAAGGTGGAAATCAAA
Zreli H1 teški lanac aminokiselinski slijed (dvostruka mutacija u Fc označena je podebljano) (SEQ ID No:34)
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDNGMAWVRQAPGKGLEWVSFISNLAYSIDYADTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCVSGTWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
H1 pune duljine, DNA (SEQ ID No:35)
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTGACAACGGAATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTTCATTCATTAGTAATTTGGCATATAGTATCGACTACGCAGACACTGTGACGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGTCAGCGGGACCTGGTTTGCTTACTGGGGCCAGGGCACACTAGTCACAGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
Zreli H2 teški lanac aminokiselinski slijed, (dvostruka mutacija u Fc označena je podebljano) (SEQ ID No:36)
EVQLVESGGGLVQPGGSLRLSCAVSGFTFSDNGMAWVRQAPGKGLEWVSFISNLAYSIDYADTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCVSGTWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTLMISRTPEVTCWVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
H2 pune duljine, DNA (SEQ ID No:37)
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGTCTCTGGATTCACCTTCAGTGACAACGGAATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTTCATTCATTAGTAATTTGGCATATAGTATCGACTACGCAGACACTGTGACGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGTCAGCGGGACCTGGTTTGCTTACTGGGGCCAGGGCACACTAGTCACAGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
Zreli H3 teški lanac, aminokiselinski slijed (dvostruka mutacija u Fc označena je podebljano) (SEQ ID No:38)
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDNGMAWVRQAPGKGLEWISFISNLAYSIDYADTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCVSGTWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
H3 pune duljine, DNA (SEQ ID No:39)
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTGACAACGGAATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCTCATTCATTAGTAATTTGGCATATAGTATCGACTACGCAGACACTGTGACGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGTCAGCGGGACCTGGTTTGCTTACTGGGGCCAGGGCACACTAGTCACAGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
Zreli laki lanac, aminokiselinski slijed (SEQ ID No:40)
DIVMTQSPLSLPVTPGEPASISCRVSQSLLHSNGYTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQTRHVPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
L1 pune duljine, DNA (SEQ ID No:41)
GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGAGTTAGTCAGAGCCTTTTACACAGTAATGGATACACCTATTTACATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATAAAGTTTCCAACCGATTTTCTGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCTCTCAAACTAGACATGTTCCGTACACGTTCGGCGGAGGGACCAAGGTGGAAATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGACAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
Optimirani H2 teški lanac, DNA (SEQ ID No:42)
GAGGTGCAGCTGGTGGAGTCTGGCGGCGGACTGGTGCAGCCTGGCGGCAGCCTGAGACTGAGCTGTGCCGTGTCCGGCTTCACCTTCAGCGACAACGGCATGGCCTGGGTGAGGCAGGCCCCTGGCAAGGGCCTGGAGTGGGTGTCCTTCATCAGCAACCTGGCCTACAGCATCGACTACGCCGACACCGTGACCGGCAGATTCACCATCAGCCGGGACAACGCCAAGAACAGCCTGTACCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGTGTGAGCGGCACCTGGTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGGCCGGAGCCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAG
Optimirani L1 laki lanac, DNA (SEQ ID No:43)
GACATCGTGATGACCCAGAGCCCCCTGAGCCTGCCCGTGACCCCTGGCGAGCCCGCCAGCATCAGCTGTAGAGTGAGCCAGAGCCTGCTGCACAGCAACGGCTACACCTACCTGCACTGGTATCTGCAGAAGCCTGGCCAGAGCCCTCAGCTGCTGATCTACAAGGTGTCCAACCGGTTCAGCGGCGTGCCTGATAGATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGAAGATCAGCAGAGTGGAGGCCGAGGATGTGGGCGTGTACTACTGCTCCCAGACCAGACACGTGCCTTACACCTTTGGCGGCGGAACAAAGGTGGAGATCAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78758806P | 2006-03-30 | 2006-03-30 | |
| PCT/EP2007/052928 WO2007113172A2 (en) | 2006-03-30 | 2007-03-27 | Antibodies against amyloid-beta peptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100115T1 true HRP20100115T1 (hr) | 2010-04-30 |
Family
ID=38284050
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100115T HRP20100115T1 (hr) | 2006-03-30 | 2010-03-02 | Protutijela protiv peptida amiloid-beta |
| HRP20140618TT HRP20140618T1 (hr) | 2006-03-30 | 2014-06-30 | Protutijela protiv beta-amiloidnog peptida |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140618TT HRP20140618T1 (hr) | 2006-03-30 | 2014-06-30 | Protutijela protiv beta-amiloidnog peptida |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US8227576B2 (hr) |
| EP (2) | EP2177536B1 (hr) |
| JP (1) | JP5103466B2 (hr) |
| KR (2) | KR101263294B1 (hr) |
| CN (2) | CN101415729B (hr) |
| AR (1) | AR060332A1 (hr) |
| AT (1) | ATE451392T1 (hr) |
| AU (1) | AU2007233831B2 (hr) |
| BR (1) | BRPI0709246A2 (hr) |
| CA (1) | CA2647808C (hr) |
| CR (1) | CR10347A (hr) |
| CY (1) | CY1109877T1 (hr) |
| DE (1) | DE602007003703D1 (hr) |
| DK (2) | DK1996621T3 (hr) |
| EA (1) | EA015654B9 (hr) |
| ES (2) | ES2338179T3 (hr) |
| HK (2) | HK1138015A1 (hr) |
| HR (2) | HRP20100115T1 (hr) |
| IL (1) | IL193695A (hr) |
| JO (1) | JO2576B1 (hr) |
| MA (1) | MA30337B1 (hr) |
| MX (1) | MX2008012483A (hr) |
| MY (1) | MY149630A (hr) |
| NO (1) | NO20083793L (hr) |
| NZ (1) | NZ571038A (hr) |
| PE (1) | PE20080181A1 (hr) |
| PL (2) | PL2177536T3 (hr) |
| PT (2) | PT2177536E (hr) |
| SI (2) | SI2177536T1 (hr) |
| TW (1) | TWI385179B (hr) |
| UA (1) | UA94734C2 (hr) |
| WO (1) | WO2007113172A2 (hr) |
| ZA (1) | ZA200807911B (hr) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| ATE512674T1 (de) | 2003-01-06 | 2011-07-15 | Angiochem Inc | Angiopep-1, verwandte verbindungen, und deren verwnedungen |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| WO2006066089A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
| CA2589860A1 (en) | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
| DK1976877T4 (en) | 2005-11-30 | 2017-01-16 | Abbvie Inc | Monoclonal antibodies to amyloid beta protein and uses thereof |
| KR20080090408A (ko) | 2005-11-30 | 2008-10-08 | 아보트 러보러터리즈 | 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법 |
| WO2009017467A1 (en) * | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| PL2046833T3 (pl) | 2006-07-14 | 2014-01-31 | Ac Immune Sa | Humanizowane przeciwciało przeciw amyloidowi beta |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| US8323654B2 (en) | 2007-05-14 | 2012-12-04 | Medtronic, Inc. | Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules |
| US7931899B2 (en) | 2007-05-14 | 2011-04-26 | Medtronic, Inc | Humanized anti-amyloid beta antibodies |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| DK3216802T3 (da) * | 2007-08-20 | 2021-01-04 | Glaxo Group Ltd | Produktionsfremgangsmåde |
| GB0718737D0 (en) * | 2007-09-25 | 2007-11-07 | Glaxo Group Ltd | Antibodies |
| NZ601858A (en) * | 2007-10-05 | 2014-03-28 | Genentech Inc | Methods and compositions for diagnosis and treatment of amyloidosis |
| US9403902B2 (en) | 2007-10-05 | 2016-08-02 | Ac Immune S.A. | Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody |
| WO2009046978A1 (en) * | 2007-10-12 | 2009-04-16 | F. Hoffmann-La Roche Ag | Protein expression from multiple nucleic acids |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| WO2009070648A2 (en) * | 2007-11-27 | 2009-06-04 | Medtronic, Inc. | Humanized anti-amyloid beta antibodies |
| PE20091449A1 (es) * | 2007-12-11 | 2009-10-07 | Glaxo Group Ltd | Proteinas de union a antigenos |
| CA2709354C (en) * | 2007-12-21 | 2014-06-17 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
| KR20110010758A (ko) | 2008-05-06 | 2011-02-07 | 글락소 그룹 리미티드 | 생물학적 활성제의 캡슐화 |
| BRPI0920209A2 (pt) | 2008-10-15 | 2015-12-22 | Angiochem Inc | conjugados de agonistas de glp-1 e usos dos mesmos |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| AU2009322043A1 (en) | 2008-12-05 | 2011-07-07 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| EP2421562B1 (en) | 2009-04-20 | 2019-03-13 | Angiochem Inc. | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
| CN102596993A (zh) * | 2009-07-02 | 2012-07-18 | 安吉奥开米公司 | 多聚体肽结合物以及其应用 |
| SG178953A1 (en) | 2009-09-11 | 2012-04-27 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
| EP2308897A1 (en) * | 2009-10-09 | 2011-04-13 | Pierre Fabre Medicament | Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer |
| TW201144437A (en) | 2010-03-03 | 2011-12-16 | Boehringer Ingelheim Int | A-beta binding polypeptides |
| JP2013523182A (ja) | 2010-04-15 | 2013-06-17 | アボット・ラボラトリーズ | アミロイドベータ結合タンパク質 |
| WO2011149461A1 (en) * | 2010-05-27 | 2011-12-01 | Medtronic, Inc. | Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules |
| JP6081356B2 (ja) | 2010-07-30 | 2017-02-15 | エーシー イミューン エス．エー． | 安全で機能的なヒト化抗βアミロイド抗体 |
| CN105348387B (zh) | 2010-08-14 | 2020-08-25 | Abbvie 公司 | β淀粉样蛋白结合蛋白 |
| TWI689314B (zh) | 2010-11-30 | 2020-04-01 | 建南德克公司 | 低親和力血腦障壁受體抗體及其用途 |
| CA2826286C (en) | 2011-01-31 | 2021-09-21 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| AU2012245260B2 (en) | 2011-04-22 | 2016-09-08 | Aptevo Research And Development Llc | Prostate-specific membrane antigen binding proteins and related compositions and methods |
| GB201113570D0 (en) * | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
| TW201400132A (zh) | 2012-05-21 | 2014-01-01 | Genentech Inc | 改善血腦屏障運送之安全性之方法 |
| RU2509155C1 (ru) * | 2012-10-25 | 2014-03-10 | Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук | Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии |
| US20160139118A1 (en) | 2013-06-19 | 2016-05-19 | Glaxosmithkline Intellectual Property (No.2) Limited | Novel assay |
| CN104558172A (zh) * | 2015-01-04 | 2015-04-29 | 东南大学 | 一种针对β淀粉样蛋白的单域重链纳米抗体及其应用 |
| CA2989400A1 (en) | 2015-06-15 | 2016-12-22 | Angiochem Inc. | Ang1005 for the treatment of leptomeningeal carcinomatosis |
| US11352426B2 (en) | 2015-09-21 | 2022-06-07 | Aptevo Research And Development Llc | CD3 binding polypeptides |
| WO2017072090A1 (en) * | 2015-10-27 | 2017-05-04 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| MX2019015914A (es) * | 2017-06-29 | 2020-08-06 | Univ Columbia | Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide. |
| US11382974B2 (en) | 2017-08-01 | 2022-07-12 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for treatment of amyloid deposition diseases |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| US12018069B2 (en) | 2018-06-28 | 2024-06-25 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for imaging amyloid deposits |
| AU2019304384A1 (en) * | 2018-07-17 | 2021-01-28 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-abeta antibody, antigen-binding fragment thereof and application thereof |
| CN113874078A (zh) | 2019-04-05 | 2021-12-31 | Tauc3生物制品有限公司 | 抗tauc3抗体及其应用 |
| CN116348487A (zh) | 2020-07-23 | 2023-06-27 | 欧萨尔普罗席纳有限公司 | 抗淀粉样β抗体 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| CN114591918B (zh) * | 2022-05-07 | 2022-07-26 | 北京第一生物化学药业有限公司 | 产生抗β-淀粉样蛋白抗体的杂交瘤细胞及其用途 |
| CN114591917B (zh) * | 2022-05-07 | 2022-09-02 | 北京第一生物化学药业有限公司 | 产生结合β-淀粉样蛋白的抗体的杂交瘤细胞及其用途 |
| KR102530956B1 (ko) * | 2022-09-08 | 2023-05-11 | 주식회사 알츠코리아 | 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5880268A (en) * | 1992-01-27 | 1999-03-09 | Icos Corporation | Modulators of the interaction between ICAM-R and αd /CD18 |
| JP3816111B2 (ja) * | 1997-04-09 | 2006-08-30 | インテレクト・ニューロサイエンシズ・インコーポレーテッド | β−アミロイド末端に特異的な組換え抗体、それをコードするＤＮＡ及びその使用法 |
| US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| AU1742200A (en) * | 1998-11-25 | 2000-06-13 | Eli Lilly And Company | Prevention and treatment of amyloid-associated disorders |
| BRPI0108676B8 (pt) * | 2000-02-24 | 2021-05-25 | Lilly Co Eli | anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos |
| WO2002038108A2 (en) * | 2000-11-03 | 2002-05-16 | The J. David Gladstone Institutes | Methods of treating disorders related to apoe |
| WO2004029629A1 (en) * | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
| ITTO20020867A1 (it) * | 2002-10-08 | 2004-04-09 | Pro Cord Spa | Schienale di sedia. |
| EP1633786A4 (en) * | 2002-10-09 | 2007-07-25 | Rinat Neuroscience Corp | METHOD FOR TREATING ALZHEIMER DISEASE WITH ANTIBODIES TO AMYLOID BETA PEPTIDE AND COMPOSITIONS THEREOF |
-
2007
- 2007-03-27 UA UAA200810923A patent/UA94734C2/ru unknown
- 2007-03-27 MX MX2008012483A patent/MX2008012483A/es active IP Right Grant
- 2007-03-27 NZ NZ571038A patent/NZ571038A/en not_active IP Right Cessation
- 2007-03-27 PL PL09178407T patent/PL2177536T3/pl unknown
- 2007-03-27 CA CA2647808A patent/CA2647808C/en not_active Expired - Fee Related
- 2007-03-27 ES ES07727401T patent/ES2338179T3/es active Active
- 2007-03-27 CN CN2007800124360A patent/CN101415729B/zh not_active Expired - Fee Related
- 2007-03-27 BR BRPI0709246-6A patent/BRPI0709246A2/pt not_active IP Right Cessation
- 2007-03-27 PL PL07727401T patent/PL1996621T3/pl unknown
- 2007-03-27 SI SI200731503T patent/SI2177536T1/sl unknown
- 2007-03-27 PT PT91784074T patent/PT2177536E/pt unknown
- 2007-03-27 DK DK07727401.7T patent/DK1996621T3/da active
- 2007-03-27 EP EP09178407.4A patent/EP2177536B1/en active Active
- 2007-03-27 SI SI200730173T patent/SI1996621T1/sl unknown
- 2007-03-27 AT AT07727401T patent/ATE451392T1/de active
- 2007-03-27 EA EA200801842A patent/EA015654B9/ru not_active IP Right Cessation
- 2007-03-27 EP EP07727401A patent/EP1996621B1/en active Active
- 2007-03-27 DE DE602007003703T patent/DE602007003703D1/de active Active
- 2007-03-27 KR KR1020087026640A patent/KR101263294B1/ko not_active IP Right Cessation
- 2007-03-27 JP JP2009502072A patent/JP5103466B2/ja not_active Expired - Fee Related
- 2007-03-27 CN CN201310338011.6A patent/CN103539857A/zh active Pending
- 2007-03-27 DK DK09178407.4T patent/DK2177536T3/da active
- 2007-03-27 US US12/294,438 patent/US8227576B2/en not_active Expired - Fee Related
- 2007-03-27 AU AU2007233831A patent/AU2007233831B2/en not_active Ceased
- 2007-03-27 WO PCT/EP2007/052928 patent/WO2007113172A2/en active Application Filing
- 2007-03-27 KR KR1020127016745A patent/KR20120093400A/ko not_active Application Discontinuation
- 2007-03-27 ES ES09178407.4T patent/ES2484967T3/es active Active
- 2007-03-27 PT PT07727401T patent/PT1996621E/pt unknown
- 2007-03-28 TW TW096110663A patent/TWI385179B/zh not_active IP Right Cessation
- 2007-03-28 JO JO200788A patent/JO2576B1/en active
- 2007-03-28 PE PE2007000354A patent/PE20080181A1/es not_active Application Discontinuation
- 2007-03-28 AR ARP070101295A patent/AR060332A1/es not_active Application Discontinuation
-
2008
- 2008-08-26 IL IL193695A patent/IL193695A/en not_active IP Right Cessation
- 2008-09-03 NO NO20083793A patent/NO20083793L/no not_active Application Discontinuation
- 2008-09-15 ZA ZA200807911A patent/ZA200807911B/xx unknown
- 2008-09-26 MY MYPI20083843A patent/MY149630A/en unknown
- 2008-10-07 CR CR10347A patent/CR10347A/es unknown
- 2008-10-15 MA MA31293A patent/MA30337B1/fr unknown
-
2009
- 2009-03-18 HK HK10104228.4A patent/HK1138015A1/xx not_active IP Right Cessation
- 2009-03-18 HK HK09102564.3A patent/HK1122311A1/xx not_active IP Right Cessation
-
2010
- 2010-03-01 CY CY20101100198T patent/CY1109877T1/el unknown
- 2010-03-02 HR HR20100115T patent/HRP20100115T1/hr unknown
-
2012
- 2012-06-08 US US13/491,810 patent/US9193784B2/en not_active Expired - Fee Related
-
2014
- 2014-06-30 HR HRP20140618TT patent/HRP20140618T1/hr unknown
-
2015
- 2015-10-13 US US14/881,428 patent/US20160024197A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100115T1 (hr) | Protutijela protiv peptida amiloid-beta | |
| ES2806500T3 (es) | Moléculas de unión al receptor de la superfamilia de TNF (factor de necrosis tumoral) y usos de las mismas | |
| RU2013129694A (ru) | Индуцирующий цитотоксичность терапевтический агент | |
| RU2019118359A (ru) | Антитело к cd73 человека | |
| HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
| HRP20160638T1 (hr) | Antigen vezujući proteini sposobni vezati timusni stromalni limfopoetin | |
| HRP20161216T1 (hr) | Farmaceutski pripravci s otpornošću na topljivi cea | |
| PE20110225A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
| PE20090329A1 (es) | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos | |
| JP2020500015A5 (hr) | ||
| RU2008129080A (ru) | Средства и способы лечения опухолевых заболеваний | |
| RU2010129558A (ru) | ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С АЛЬФА-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4Rα)-173 | |
| UY30524A1 (es) | Anticuerpos dirigidos a avb(beta)6 y sus usos | |
| JP2010532764A5 (hr) | ||
| JP2008508859A5 (hr) | ||
| HRP20160494T1 (hr) | Antigen-vezujući proteini za proproteinsku konvertazu subtilizin keksin tipa 9 (pcsk9) | |
| RU2004107695A (ru) | Способы удаления амилоида с помощью анти-амилоидных антител | |
| JP2011526785A5 (hr) | ||
| PE20070183A1 (es) | Anticuerpos monoclonales anti-trkb | |
| MX2009003093A (es) | Composiciones y metodos relacionados con anticuerpos del receptor de glucagon. | |
| RU2010136940A (ru) | Антитела против альфа5-бета1 и их применение | |
| HRP20090326T1 (hr) | Sintetičke domene imunoglobulina sa vezujućim svojstvima izgrađenim u područjima molekule različitim od komplementarno određujućih područja | |
| RS53793B1 (en) | HUMANIZED ANTIBODIES AGAINST BETA AMYLOID | |
| JP2006526414A5 (hr) | ||
| RU2009128064A (ru) | Антитела к cd44 |